A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML

Clinical trial NCT02040506 · COMPLETED

Trial details

NCT number: NCT02040506
Sponsor: Igenica Biotherapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myelogenous Leukemia Acute Myeloid Leukemia

Start date: 2014-02-01
Primary completion: 2015-03-01
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.